Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22909373 | 0.82 | AR (0.45) | HDAC6HDAC11HDAC8MEN1KMT2A | |
| SCHEMBL29729050 | 0.80 | HDAC6 (0.39) | MAOBHDAC6ALOX5APFEN1 | |
| SCHEMBL22909262 | 0.80 | HDAC6 (0.39) | MAOBHDAC6ALOX5APFEN1 | |
| SCHEMBL22909451 | 0.79 | TSHR (0.48) | MAOBTSHRALOX5APFEN1 | |
| SCHEMBL29671295 | 0.79 | ALOX5AP (0.41) | PARP10MAOBPARP1MEN1KMT2A | |
| SCHEMBL29671227 | 0.78 | CYP19A1 (0.50) | MAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL22909160 | 0.71 | MAPT (0.36) | HDAC6HDAC11HDAC8HDAC3TSHR | |
| SCHEMBL29729048 | 0.71 | CA1 (0.31) | HDAC6HDAC11HDAC8HDAC3 | |
| SCHEMBL22909579 | 0.70 | MAOB (0.43) | MAOBALDH1A1 | |
| SCHEMBL22909370 | 0.70 | SMN1; SMN2 (0.43) | PARP10MAOBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021009568-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | PARP10 4112/4885MAOB 3430/4885HDAC6 1241/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | PARP10 3367/4885MAOB 1549/4885HDAC6 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.